Acurx Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Initiated a pivotal rCDI trial for ibezapolstat, leveraging strong phase II results and new FDA guidance that may allow single pivotal trials. Cash position improved to $9.3M, with reduced expenses and new capital raised to fund ongoing clinical programs.
Fiscal Year 2025
-
Ibezapolstat advanced with strong phase II results and a new rCDI trial launching in late 2026, supported by improved financials and a strengthened patent position. Lower expenses and ongoing funding initiatives position the company for pivotal trials and potential regulatory acceleration.
-
Q3 2025 saw improved financials with reduced losses and increased cash, driven by cost controls and new capital. Regulatory and partnership progress continues for ibezapolstat, with key scientific milestones and expanded IP. Major partnership news may be forthcoming.
-
Q2 2025 saw improved financials with reduced losses and expenses, successful capital raises, and positive clinical progress for ibezapolstat. Strategic partnerships and cost control remain priorities as the company advances toward phase III trials.
-
Q1 2025 saw strengthened liquidity through $3.6M in new funding, reduced expenses, and a narrowed net loss. Positive regulatory and clinical milestones position the lead program for phase III, pending additional funding, with new patents bolstering the pipeline.
Fiscal Year 2024
-
Advancing ibezapolstat to phase III trials with strong phase II results and regulatory alignment from FDA and EMA. Cash position decreased to $3.7M, with ongoing funding efforts and recent offerings. Phase III start expected in 2025, pending additional financing.
-
Positive phase II results for ibezapolstat in C. difficile infection support phase III readiness, with strong regulatory progress and new patents. Cash reserves declined to $5.8M, and non-dilutive funding is being pursued for pivotal trials.
-
Phase III readiness for ibezapolstat confirmed, with international trials planned and a new U.S. patent secured. Q2 net loss widened to $4.1M as R&D and G&A expenses rose; multiple non-dilutive funding and partnership options are being pursued to support upcoming trials.